In 2025, Natco Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Natco Pharma has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 28,494.95a | 28,403.25a | 24,890b | |
Total Scope 2 | ||||
Unspecified Calculation Method | 43,630.35a | 41,763.62a | 43,870b | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 54.9641a | 59.2336a | 75.7041b |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Natco Pharma amounted to 72,125.3 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Natco Pharma increased by 2.79%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2025, the total Scope 1 emissions of Natco Pharma were 28,494.95 metric tons of CO₂ equivalent (tCO₂e).a
Since 2021, Natco Pharma's Scope 1 emissions have increased by 114.81%, reflecting a rising long-term trend in Scope 1 emissions over time.ac
Compared to the previous year (2024), Natco Pharma's Scope 1 emissions remained relatively stable, indicating that Natco Pharma's emissions have plateaued with no significant change in its operational footprint.a
In 2025, Natco Pharma reported Scope 2 greenhouse gas (GHG) emissions of 43,630.35 tCO₂e without specifying the calculation method.a
Since 2021, Natco Pharma's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Natco Pharma's emissions have plateaued with no significant change in its energy consumption footprint.ac
Compared to the previous year (2024), Natco Pharma's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Natco Pharma's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2025, Natco Pharma reported its Scope 2 emissions using an unspecified methodology.a
In 2025, Natco Pharma reported Scope 1 greenhouse gas (GHG) emissions of 28,494.95 tCO₂e and total revenues of USD 518 millions. This translates into an emissions intensity of 54.96 tCO₂e per millions USD.a
In 2025, Natco Pharma reported a Scope 1 emissions intensity of 54.96 tCO₂e per millions USD. Compared to the peer group median of 25.65, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2025, Natco Pharma ranked 17 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Natco Pharma is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a